APG Asset Management N.V. Reduces Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• APG Asset Management N.V. reduced its stake in Teva Pharmaceutical Industries by 32.3%, owning 46,665 shares valued at $664,000 after selling 22,229 shares in the first quarter.
• Other institutional investors significantly increased their stakes in Teva, with Harel Insurance Investments raising their holdings by 197,885.2% during the same period.
• Teva Pharmaceutical reported earnings of $0.66 per share for the last quarter, exceeding expectations, but revenue was below estimates at $4.18 billion.

APG Asset Management N.V. cut its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 32.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,665 shares of the company's stock after selling 22,229 shares during the quarter. APG Asset Management N.V.'s holdings in Teva Pharmaceutical Industries were worth $664,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of TEVA. Harel Insurance Investments & Financial Services Ltd. lifted its stake in Teva Pharmaceutical Industries by 197,885.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock worth $338,989,000 after purchasing an additional 22,044,407 shares in the last quarter. Duquesne Family Office LLC lifted its stake in Teva Pharmaceutical Industries by 530.1% in the 4th quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock worth $198,303,000 after purchasing an additional 7,569,450 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in Teva Pharmaceutical Industries by 472.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company's stock worth $96,078,000 after buying an additional 5,186,592 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in Teva Pharmaceutical Industries by 416.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 5,983,928 shares of the company's stock worth $91,973,000 after buying an additional 4,824,247 shares in the last quarter. Finally, Nuveen LLC purchased a new position in Teva Pharmaceutical Industries in the 1st quarter worth approximately $40,827,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TEVA has been the subject of a number of research reports. UBS Group cut their price target on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Truist Financial initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price target for the company. The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a "buy" rating and a $24.00 price target for the company. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $21.00 to $23.00 in a research note on Monday, May 12th. Two research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $24.71.

Insider Activity

In related news, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the sale, the insider directly owned 6,774 shares in the company, valued at $102,693.84. The trade was a 47.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Matthew Shields sold 6,206 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the sale, the executive vice president owned 9,989 shares in the company, valued at $170,012.78. The trade was a 38.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 65,001 shares of company stock worth $996,958 in the last quarter. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock traded up $0.37 during trading hours on Monday, hitting $18.41. 7,153,308 shares of the company's stock were exchanged, compared to its average volume of 10,852,338. The company has a market capitalization of $21.11 billion, a PE ratio of -115.04, a PEG ratio of 1.09 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $22.80. The business's 50 day simple moving average is $16.89 and its 200-day simple moving average is $16.34. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. The firm had revenue of $4.18 billion during the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The company's quarterly revenue was up .3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.